🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Liping Dou clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Liping Dou as lead sponsor. Synced 27 Sep 2026
7Current trials
5Recruiting now
2Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Liping Dou is the lead sponsor of 7 current clinical trials in our China register. 5 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Blinatumomab and Selinexor. The most-studied condition is Lymphoma.

ClinicalTrials.gov trials by status

  • Recruiting571%
  • Active, closed229%

Trials by phase

  • Phase 2343%
  • Phase 1/2343%
  • Phase 1114%
01

Clinical trials sponsored by Liping Dou

7 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy
NCT07779018 · ClinicalTrials.gov ↗ · Lymphoma
Phase 2 Recruiting 2026-04 China
Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
NCT07677878 · ClinicalTrials.gov ↗ · ALL (Acute B-Lymphoblastic Leukemia)
Phase 1 Recruiting 2024-12 China
Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
NCT07575919 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia
Phase 1/2 Recruiting 2026-01 China
Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia
NCT07575971 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia
Phase 1/2 Recruiting 2026-01 China
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
NCT07587840 · ClinicalTrials.gov ↗ · Lymphoma
Phase 2 Recruiting 2026-01 China
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
NCT07651475 · ClinicalTrials.gov ↗ · R/R AML
Phase 2 Active, closed 2026-03 China
A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT
NCT07779031 · ClinicalTrials.gov ↗ · Acute Myeloid Leukaemia (AML), MDS (Myelodysplastic Syndrome)
Drug: Selinexor
Phase 1/2 Active, closed 2025-05 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Liping Dou trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Liping Dou trials

6 conditions
Lymphoma2B-cell Acute Lymphoblastic Leukemia2ALL (Acute B-Lymphoblastic Leukemia)1R/R AML1Acute Myeloid Leukaemia (AML)1MDS (Myelodysplastic Syndrome)1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China75

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Lymphoma

SponsorTrials
Chinese PLA General Hospital3
Bellicum Pharmaceuticals2
Treeline Biosciences2
University Hospital, Angers2
Byondis1
Turning Point Therapeutics1
Canwell Biotech1
L & L Bio Co., Ltd., Ningbo, China1
Erasme University Hospital1
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III1

Sponsors with the most current trials registered for this condition.

06

Questions about Liping Dou trials

How many clinical trials does Liping Dou sponsor?

Liping Dou is the lead sponsor of 7 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are Liping Dou trials recruiting?

Yes. 5 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Liping Dou testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are Blinatumomab (1) and Selinexor (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.